Overview

Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer

Status:
Active, not recruiting

Trial end date:
2021-05-01

Target enrollment:

Participant gender:

Summary

RATIONALE: Androgens can cause the growth of prostate cancer cells. Luteinizing hormone-releasing hormone agonists may lessen the amount of androgens made by the body. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. Giving luteinizing hormone-releasing hormone agonist together with an iodine I 125 implant may be an effective treatment for patients with prostate cancer. PURPOSE: This randomized phase III trial is studying how well giving luteinizing hormone-releasing hormone agonist therapy together with an iodine I 125 implant works with or without additional luteinizing hormone-releasing hormone agonist therapy in treating patients with previously untreated prostate cancer.

Phase:

Phase 3

Details

Lead Sponsor:

Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Translational Research Informatics Center, Kobe, Hyogo, Japan

Collaborator:

The Jikei University School of Medicine

Treatments:

Cadexomer iodine
Iodine
Prolactin Release-Inhibiting Factors